膜荚黄芪毛状根中异黄酮成分的反相高效液相色谱分析

对膜荚黄芪毛状根中6种异黄酮成分进行了反相高效液相色谱法测定。色谱柱为NucleosilC₁₈柱,流动相为甲醇—水(3∶2和3∶1,v/v),检测波长为254nm和280nm。6种异黄酮成分为:10-羟基-3,9-二甲氧基紫檀烷,(3R)8,2’-二羟基-7,4’-二甲氧基异黄烷,芒柄花素(7-羟基-4’-甲氧基异黄酮),8,3’-二羟基-7,4’-二甲氧基异黄酮,2’-羟基-3’,4’-二甲氧基异黄烷-7-O-葡萄吡喃糖甙,毛蕊异黄酮(7,3’-二羟基-4’-甲氧基异黄酮)。异黄酮浓度在2.5～12.5μg范围内与峰面积有良好的线性关系;加样回收率为96.47%～103.33%;精密度试验相对标准偏差为2.57%～6.52%;测得黄芪毛状根中6种异黄酮成分的含量在0.0005%～0.0065%之间。     

Positive and negative interactions in the behavioural expression of D1 and D2 receptor stimulation in a model of Parkinsonism: role of priming.

Previous exposure to a dopaminergic agonist (priming) strongly potentiates contralateral turning behaviour in response to D1 and D2 agonists in unilaterally 6-hydroxydopamine-lesioned rats. In order to study the influence of priming on the behavioural interaction of D1 and D2 receptors, we examined the effect of selective D1 and D2 receptor blockade on the contralateral turning induced by the mixed D2/D2 agonist apomorphine in drug-naive and primed 6-hydroxydopamine-lesioned rats. In drug-naive rats, apomorphine induced a dose-related, apparently monophasic rotation curve. Administration of selective D1 (SCH 23390) or D2 (raclopride) antagonists abolished the contralateral turning induced by 0.1 mg/kg of apomorphine and partially inhibited that induced by 0.5 mg/kg. In primed rats low doses of apomorphine (0.05 mg/kg) induced an apparently monophasic contralateral turning which was reduced by D1 receptor blockade and completely abolished by D2 receptor blockade; a higher dose of apomorphine (0.1 mg/kg) instead elicited a biphasic (two-peak) pattern of rotation. After this dose of the agonist, blockade of D1 or D2 receptors abolished the second peak of rotation but, while D1 blockade reduced the total number of turns, D2 blockade failed to do so. Quantitative analysis of the interaction between D1 and D2 receptors in the overall turning effect, as well as in the time-course of turning behaviour, indicates that D1 and D2 receptors interact not only positively but also negatively. After higher doses of apomorphine, both negative and positive interactions take place sequentially during the time-course of apomorphine action and provide a clue for explaining the two-peak pattern of rotation observed after apomorphine in rats previously exposed to the drug.     

Cytoskeletal alterations might account for the phylogenetic vulnerability of the human brain to Alzheimer's disease

A theory is presented here in the attempt to explain why Alzheimer's disease (AD) primarily affects areas of the human brain that have been acquired recently in phylogenesis. Disturbances in cytoskeletal function are proposed to play a fundamental role in triggering the sequence of pathologic events leading to the occurrence of AD-related histopathological markers and to the degeneration and death of neurons. These deficits are supposed to occur more likely in neuronal populations that possess a high degree of plasticity, the substrate of memory functions, and that constitute, in fact, the phylogenetically new telencephalic regions of the human brain.     

甘肃省1995年急性弛缓性麻痹病例病毒学监测

甘肃省１９９５年共报告１５岁以下儿童急性弛缓性麻痹（ＡＦＰ）病例９０例，发病率为１．３２／１０万。省脊髓灰质炎（脊灰）实验室收到ＡＦＰ病例的粪便标本共７９例，占８８％；双份合格粪便标本采集率为６８％（６１／９０）；粪便标本７天内送省脊灰实验室的占６５％（５２／７９）收到粪便标本后７天内分离培养的占８９％（７０／７９）；分离培养结果及时报告率为８７％（６９／７９）。病毒分离阳性率１３．９２％（１１／７９），其中脊灰病毒（ＰＶ）Ⅱ型５株，Ⅲ型１株，非脊灰肠道病毒（ＮＰＥＶ）５株。收到ＡＦＰ病例密切接触者粪便标本３ｌ８份，病毒分离阳性率５．６６％（１８／３１８），其中ＰＶⅡ型８株，ＮＰＥＶ１０株。全部送检粪便标本ＮＰＥＶ分离率３．７８％（１５／３９７）。所分离的ＰＶ均为疫苗株，且Ⅱ型居多。     

Daily nutrient intake represents a modifiable determinant of nutritional status in chronic haemodialysis patients.

BACKGROUND: In maintenance haemodialysis patients, daily food intake is changeable; however, its relationship with nutritional status is unexplored. This study aimed to evaluate the isolated, long-term effect of daily nutrient intake on nutritional status in haemodialysis patients. METHODS: We performed a prospective 1-year controlled study in 27 chronic haemodialysis patients, without recognized risk factors for malnutrition. Each day for 1 week, four times in the year, we measured protein nitrogen appearance, and assessed dietary protein (DPI) and energy (DEI) intake from dietary diaries. We compared the nutritional outcome of patients spontaneously reducing nutrient intake below the threshold of 0.8 g/kg body weight/day for DPI and 25 kcal/kg body weight/day for DEI during the week (LOW, n = 8), with controls at adequate nutrient intake (CON, n = 19). An interventional 6-month study was then carried out in LOW to verify the cause-effect relationship. RESULTS: All patients showed a day-by-day reduction of whole nutrient intake during interdialytic period, which was mostly relevant in the third interdialytic day (L3). During the 1-year study, even in the presence of adequate dialysis dose and normal inflammatory indexes, body weight (68.0 +/- 5.5 to 65.8 +/- 5.9 kg), serum albumin (3.96 +/- 0.07 to 3.66 +/- 0.06 g/dl) and creatinine (9.2 +/- 1.1 to 8.1 +/- 0.7 mg/dl) significantly decreased in LOW but not in CON. Diaries evidenced in LOW a reduced number of meals at L3 that was explained by the fear of excessive interdialytic weight gain. During the interventional study, daily DPI and DEI increased at L3; this was associated with a significant increment of body weight, and serum albumin and creatinine levels. CONCLUSIONS: In maintenance haemodialysis patients the persistent, marked reduction of daily nutrient intake, even if limited to a single day of the week, is an independent determinant of reversible impairment of nutritional status.     

Phosphatidylcholine does not affect peritoneal transport of intact rabbits

Ultrafiltration and solute transport during 60-min peritoneal dialyses of normal rabbits with intraperitoneal administration of phosphatidylcholine were compared to control values. The ultrafiltration rate of 0.27 mL/Kg/min did not increase when phosphatidylcholine was added. This agent had no effect on the ultrafiltration coefficient, sodium mass transport or solute clearances. Previously reported beneficial results with this agent could be due to repletion of a deficiency or an effect of the organic solvent. More studies of safety and efficacy of phosphatidylcholine are warranted before widespread clinical use.     

Stopping a medical research project for financial reasons

Sir, We are writing to provide some clarifications on the EditorialComment by Drüeke et al. [1]. We would have been happyto provide these very same clarifications had we been fairlyinvited to do so before the publication of the article. First of all, we would like to